Biolight Life Sciences Ltd
TASE:BOLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biolight Life Sciences Ltd
Research & Development
Biolight Life Sciences Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biolight Life Sciences Ltd
TASE:BOLT
|
Research & Development
-₪4.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Compugen Ltd
NASDAQ:CGEN
|
Research & Development
-$22.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Biolight Life Sciences Ltd
Glance View
BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseases. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
See Also
What is Biolight Life Sciences Ltd's Research & Development?
Research & Development
-4.7m
ILS
Based on the financial report for Sep 30, 2025, Biolight Life Sciences Ltd's Research & Development amounts to -4.7m ILS.
What is Biolight Life Sciences Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
11%
Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for Biolight Life Sciences Ltd have been 15% over the past three years , -1% over the past five years , and 11% over the past ten years .
